Want to see ES:RJF full AI Analyst Report?
RJF Stock Chart & Stats
€2.64
€0.02(0.76%)
At close: 4:00 PM EDT
€2.64
€0.02(0.76%)
Day’s Range― - ―
52-Week Range€2.32 - €3.35
Previous CloseN/A
Volume24.20K
Average Volume (3M)44.99K
Market Cap
€220.66M
Enterprise Value€329.17
Total Cash (Recent Filing)€21.58M
Total Debt (Recent Filing)€103.27M
Price to Earnings (P/E)31.6
Beta0.38
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.73%
Share Statistics
EPS (TTM)0.05
Shares Outstanding82,883,400
10 Day Avg. Volume48,066
30 Day Avg. Volume44,988
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)0.96
Price to Sales (P/S)0.63
P/FCF Ratio-15.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)€358.95M
Bulls Say, Bears Say
Bulls Say
Business Model DiversificationA dual revenue model (branded/specialty medicines plus CDMO services) provides structural balance: product sales drive margin upside while contract manufacturing supplies recurring fee-based revenue and capacity utilization, reducing single-source demand risk and supporting steady cash flow over cycles.
Moderate Leverage And Equity GrowthHistorically moderate debt levels and gradual equity growth create a resilient capital structure. This affords the company room to fund working capital and targeted investments without excessive refinancing risk, supporting durable operational continuity and strategic optionality over the medium term.
Pre-2025 Revenue And Margin StabilityA multi-year track record of revenue growth and ~10–11% EBITDA margins through 2024 indicates underlying product demand and operational scalability. That historical stability implies the business model can re-assert profitable growth if 2025-specific headwinds are addressed and volumes/pricing recover.
Bears Say
Sharp 2025 Revenue & Margin HitA large year-on-year revenue decline and collapse in operating margins materially undermine sustainable earnings power. Such deterioration reduces retained earnings available for reinvestment and makes achieving prior returns difficult without clear signs of demand recovery or cost restructuring.
Weak And Volatile Cash GenerationA swing to deeply negative free cash flow and uneven operating cash undermines self-funded investment and increases reliance on external financing. Persistent cash volatility raises execution risk for capex, R&D, and capacity commitments, constraining durable growth and strategic flexibility.
Lower ROE And Rising Leverage In 2025Declining ROE coupled with higher leverage reduces capital efficiency and shareholder return potential. This combination increases sensitivity to further profit shocks, limits ability to pursue M&A or expansion without additional financing, and raises the long-term cost of capital.
LABORATORIO REIG JOFRE News
RJF FAQ
What was LABORATORIO REIG JOFRE S.A.’s price range in the past 12 months?
LABORATORIO REIG JOFRE S.A. lowest stock price was €2.32 and its highest was €3.35 in the past 12 months.
What is LABORATORIO REIG JOFRE S.A.’s market cap?
LABORATORIO REIG JOFRE S.A.’s market cap is €220.66M.
When is LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date?
LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date is Nov 13, 2026 which is in 91 days.
How were LABORATORIO REIG JOFRE S.A.’s earnings last quarter?
LABORATORIO REIG JOFRE S.A. released its earnings results on Jul 31, 2026. The company reported €0.005 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is LABORATORIO REIG JOFRE S.A. overvalued?
According to Wall Street analysts LABORATORIO REIG JOFRE S.A.’s price is currently Overvalued.
Does LABORATORIO REIG JOFRE S.A. pay dividends?
LABORATORIO REIG JOFRE S.A. pays a Annually dividend of €0.019 which represents an annual dividend yield of 0.73%. See more information on LABORATORIO REIG JOFRE S.A. dividends here
What is LABORATORIO REIG JOFRE S.A.’s EPS estimate?
LABORATORIO REIG JOFRE S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LABORATORIO REIG JOFRE S.A. have?
LABORATORIO REIG JOFRE S.A. has 82,883,400 shares outstanding.
What happened to LABORATORIO REIG JOFRE S.A.’s price movement after its last earnings report?
LABORATORIO REIG JOFRE S.A. reported an EPS of €0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.377%.
Which hedge fund is a major shareholder of LABORATORIO REIG JOFRE S.A.?
Currently, no hedge funds are holding shares in ES:RJF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LABORATORIO REIG JOFRE S.A.
Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs, over-the-counter (OTC) products, medical devices, and cosmetics. The company's offerings are categorized into several key areas: advanced pharmaceutical technologies, which include antibiotics and injectable formulations; specialized healthcare solutions targeting dermatological, musculoskeletal (joint health and pain), women's health, respiratory/ENT, and pediatric needs; and consumer health items marketed under its Forté Pharma brand. Furthermore, Laboratorio Reig Jofre provides contract development and manufacturing (CDMO) as well as contract manufacturing organization (CMO) services. Founded in 1929 and headquartered in Sant Joan Despí, Spain, the company sells its products directly in seven countries and collaborates with business partners to reach approximately 70 other nations. It operates as a subsidiary of Reig Jofre Investments SL.